Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued research reports about the company. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Scotiabank increased their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $791.05.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $796.55 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11. The stock has a market cap of $83.72 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 2.17 and a beta of 0.39. The firm has a fifty day moving average price of $738.12 and a 200 day moving average price of $628.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the company posted $12.46 earnings per share. The business’s quarterly revenue was up .9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC lifted its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $226,000. Integrity Alliance LLC. acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $579,000. Geneos Wealth Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 9.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 757 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 67 shares during the period. Finally, Jacobi Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 8.1% during the 1st quarter. Jacobi Capital Management LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $904,000 after acquiring an additional 107 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.